Accumulation of memory precursor cd8 t cells in regressing tumors following combination therapy with vaccine and anti-pd-1 antibody

Lavakumar Karyampudi, Purushottam Lamichhane, Adam D. Scheid, Kimberly R. Kalli, Barath Shreeder, James W. Krempski, Marshall D. Behrens, Keith L Knutson

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Immunosuppression in the tumor microenvironment blunts vaccine-induced immune effectors. PD-1/B7-H1 is an important inhibitory axis in the tumor microenvironment. Our goal in this study was to determine the effect of blocking this inhibitory axis during and following vaccination against breast cancer. We observed that using anti- PD-1 antibody and a multipeptide vaccine (consisting of immunogenic peptides derived from breast cancer antigens, neu, legumain, and b-catenin) as a combination therapy regimen for the treatment of breast cancer- bearing mice prolonged the vaccine-induced progression-free survival period. This prolonged survival was associated with increase in number of Tc1 and Tc2 CD8 T cells with memory precursor phenotype, CD27IL- 7RhiT-betlo, and decrease in number of PD-1 dendritic cells (DC) in regressing tumors and enhanced antigen reactivity of tumor-infiltrating CD8 T cells. It was also observed that blockade of PD-1 on tumor DCs enhanced IL- 7R expression on CD8 T cells. Taken together, our results suggest that PD-1 blockade enhances breast cancer vaccine efficacy by altering both CD8 T cell andDCcomponents of the tumor microenvironment. Given the recent success of anti-PD-1 monotherapy, our results are encouraging for developing combination therapies for the treatment of patients with cancer in which anti-PD-1 monotherapy alone may be ineffective (i.e., PD-L1-negative tumors).

Original languageEnglish (US)
Pages (from-to)2974-2985
Number of pages12
JournalCancer Research
Volume74
Issue number11
DOIs
StatePublished - Jun 1 2014

Fingerprint

Active Immunotherapy
Tumor Microenvironment
Breast Neoplasms
T-Lymphocytes
Vaccines
Antibodies
asparaginylendopeptidase
Neoplasms
Catenins
Cancer Vaccines
Neoplasm Antigens
Therapeutics
Immunosuppression
Dendritic Cells
Disease-Free Survival
Vaccination
Phenotype
Antigens
Peptides
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Accumulation of memory precursor cd8 t cells in regressing tumors following combination therapy with vaccine and anti-pd-1 antibody. / Karyampudi, Lavakumar; Lamichhane, Purushottam; Scheid, Adam D.; Kalli, Kimberly R.; Shreeder, Barath; Krempski, James W.; Behrens, Marshall D.; Knutson, Keith L.

In: Cancer Research, Vol. 74, No. 11, 01.06.2014, p. 2974-2985.

Research output: Contribution to journalArticle

Karyampudi, Lavakumar ; Lamichhane, Purushottam ; Scheid, Adam D. ; Kalli, Kimberly R. ; Shreeder, Barath ; Krempski, James W. ; Behrens, Marshall D. ; Knutson, Keith L. / Accumulation of memory precursor cd8 t cells in regressing tumors following combination therapy with vaccine and anti-pd-1 antibody. In: Cancer Research. 2014 ; Vol. 74, No. 11. pp. 2974-2985.
@article{087d478d540f431f9505381f03f21369,
title = "Accumulation of memory precursor cd8 t cells in regressing tumors following combination therapy with vaccine and anti-pd-1 antibody",
abstract = "Immunosuppression in the tumor microenvironment blunts vaccine-induced immune effectors. PD-1/B7-H1 is an important inhibitory axis in the tumor microenvironment. Our goal in this study was to determine the effect of blocking this inhibitory axis during and following vaccination against breast cancer. We observed that using anti- PD-1 antibody and a multipeptide vaccine (consisting of immunogenic peptides derived from breast cancer antigens, neu, legumain, and b-catenin) as a combination therapy regimen for the treatment of breast cancer- bearing mice prolonged the vaccine-induced progression-free survival period. This prolonged survival was associated with increase in number of Tc1 and Tc2 CD8 T cells with memory precursor phenotype, CD27IL- 7RhiT-betlo, and decrease in number of PD-1 dendritic cells (DC) in regressing tumors and enhanced antigen reactivity of tumor-infiltrating CD8 T cells. It was also observed that blockade of PD-1 on tumor DCs enhanced IL- 7R expression on CD8 T cells. Taken together, our results suggest that PD-1 blockade enhances breast cancer vaccine efficacy by altering both CD8 T cell andDCcomponents of the tumor microenvironment. Given the recent success of anti-PD-1 monotherapy, our results are encouraging for developing combination therapies for the treatment of patients with cancer in which anti-PD-1 monotherapy alone may be ineffective (i.e., PD-L1-negative tumors).",
author = "Lavakumar Karyampudi and Purushottam Lamichhane and Scheid, {Adam D.} and Kalli, {Kimberly R.} and Barath Shreeder and Krempski, {James W.} and Behrens, {Marshall D.} and Knutson, {Keith L}",
year = "2014",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-13-2564",
language = "English (US)",
volume = "74",
pages = "2974--2985",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Accumulation of memory precursor cd8 t cells in regressing tumors following combination therapy with vaccine and anti-pd-1 antibody

AU - Karyampudi, Lavakumar

AU - Lamichhane, Purushottam

AU - Scheid, Adam D.

AU - Kalli, Kimberly R.

AU - Shreeder, Barath

AU - Krempski, James W.

AU - Behrens, Marshall D.

AU - Knutson, Keith L

PY - 2014/6/1

Y1 - 2014/6/1

N2 - Immunosuppression in the tumor microenvironment blunts vaccine-induced immune effectors. PD-1/B7-H1 is an important inhibitory axis in the tumor microenvironment. Our goal in this study was to determine the effect of blocking this inhibitory axis during and following vaccination against breast cancer. We observed that using anti- PD-1 antibody and a multipeptide vaccine (consisting of immunogenic peptides derived from breast cancer antigens, neu, legumain, and b-catenin) as a combination therapy regimen for the treatment of breast cancer- bearing mice prolonged the vaccine-induced progression-free survival period. This prolonged survival was associated with increase in number of Tc1 and Tc2 CD8 T cells with memory precursor phenotype, CD27IL- 7RhiT-betlo, and decrease in number of PD-1 dendritic cells (DC) in regressing tumors and enhanced antigen reactivity of tumor-infiltrating CD8 T cells. It was also observed that blockade of PD-1 on tumor DCs enhanced IL- 7R expression on CD8 T cells. Taken together, our results suggest that PD-1 blockade enhances breast cancer vaccine efficacy by altering both CD8 T cell andDCcomponents of the tumor microenvironment. Given the recent success of anti-PD-1 monotherapy, our results are encouraging for developing combination therapies for the treatment of patients with cancer in which anti-PD-1 monotherapy alone may be ineffective (i.e., PD-L1-negative tumors).

AB - Immunosuppression in the tumor microenvironment blunts vaccine-induced immune effectors. PD-1/B7-H1 is an important inhibitory axis in the tumor microenvironment. Our goal in this study was to determine the effect of blocking this inhibitory axis during and following vaccination against breast cancer. We observed that using anti- PD-1 antibody and a multipeptide vaccine (consisting of immunogenic peptides derived from breast cancer antigens, neu, legumain, and b-catenin) as a combination therapy regimen for the treatment of breast cancer- bearing mice prolonged the vaccine-induced progression-free survival period. This prolonged survival was associated with increase in number of Tc1 and Tc2 CD8 T cells with memory precursor phenotype, CD27IL- 7RhiT-betlo, and decrease in number of PD-1 dendritic cells (DC) in regressing tumors and enhanced antigen reactivity of tumor-infiltrating CD8 T cells. It was also observed that blockade of PD-1 on tumor DCs enhanced IL- 7R expression on CD8 T cells. Taken together, our results suggest that PD-1 blockade enhances breast cancer vaccine efficacy by altering both CD8 T cell andDCcomponents of the tumor microenvironment. Given the recent success of anti-PD-1 monotherapy, our results are encouraging for developing combination therapies for the treatment of patients with cancer in which anti-PD-1 monotherapy alone may be ineffective (i.e., PD-L1-negative tumors).

UR - http://www.scopus.com/inward/record.url?scp=84901598853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901598853&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-2564

DO - 10.1158/0008-5472.CAN-13-2564

M3 - Article

C2 - 24728077

AN - SCOPUS:84901598853

VL - 74

SP - 2974

EP - 2985

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11

ER -